Clinical Study with Bromperidol, a New Butyrophenone Derivative

Abstract

20 psychotic - predominantly schizophrenic - patients underwent treatment with the new butyrophenone derivative bromperidol for a period of 4 weeks; the drug was administered in the form of 1 mg tablets. The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose. 19 patients finished the trial, and in 18 cases the therapeutic result was considered very good to good. These results were confirmed by statistical analysis. Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. The therapeutic value of this new substance will be demonstrated by a double-blind study.

Tissue Distribution Studies of [18f]haloperidol, [18f]-β-(4-fluorobenzoyl)propionic acid, and [82br]bromperidol by External Scintigraphy

“…Data obtained in the rat seem to indicate that VII may enter the brain at a faster rate than 11. This finding apparently is in agreement with the pharmacological observation that VII has a faster onset of action than I1 (5,6). However, the dose of 82Br-VII administered to rats was much larger than that of 'WII.…”

Der Einfluss von Diagnose, Klinik und Geschlecht auf die Wirkung von Bromperidol

“…In mehreren offenen klinischen Prüfungen wurde die antipsychotische Wir kung von Bromperidol aufgezeigt (Bataille, 1978, Clarysse, 1978Gardner, 1978;Haase et al, 1978;Hermans, 1978;Pöldinger et al, 1977;Weiser, 1978). Auf die nicht sehr ausgeprägte sedierende Wirkungskomponente von Bromperidol haben vor allem Brasseur (1978) und Fleischhauer (1978 hingewiesen.…”

Bromperidol Maintenance in Schizophrenia*

“…In a previous publication (l) we reported a 4-week doubleblind clinical trial comparing bromperidol, 2 4-4-(4-bromophenyl)-4-hydroxypiperidono-4-butyrophenone (2)(3)(4)(5)(6), with haloperidol, a butyrophenone, the neuroleptic most frequently employed in the treatment of schizophrenia. Significant improvement occurred for both treatment groups with no differences between the groups in therapeutic potential, pattern of treatment emergent side-effects, or speed of onset of activity.…”